E. S. Winkler

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

This study shows that nasal delivery of IFN-λ protects mice against SARS-CoV-2 variants including Omicron in both upper and lower respiratory tracts without causing excessive inflammation.

The paper identifies host susceptibility loci for SARS-CoV and SARS-CoV-2 using GWAS and Collaborative Cross datasets, validating CCR9 as a key regulator of severe disease outcomes across species.

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

This study evaluates the protective efficacy of modified miniproteins against SARS-CoV-2 in mice, showing reduced viral burden and prevention of lung disease.

The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

This study shows SARS-CoV-2 infects human engineered heart tissues, causing myocarditis-like features, and identifies ACE2 and proteases as entry factors.

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.